ADAMTSL2 and metabolic dysfunction-associated steatotic liver disease: ADAMTSL2 regulates the extracellular microenvironment29, is associated with myocardial fibrosis30 and adverse outcomes in patients with heart failure31 and was shown to be a biomarker to identify significant and advanced fibrosis in patients with MASLD in the LITMUS Metacohort14.